Cantor Fitzgerald analyst Charles Duncan initiated coverage of GH Research (GHRS) with an Overweight rating and no price target GH Research is ...

GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...

Sarah Napthali lowers her voice over lunch when our conversation veers to the names of the drugs she used: LSD, MDMA, ...

The results come from a phase 2a study of BPL-003, a novel formulation of 5-MeO-DMT (sometimes called mebufotenin), which is a psychoactive compound found in a wide variety of plant species ...

The money is also earmarked for a phase 1 dose-ranging study on an intranasal formulation of 5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine), a psychedelic compound found in plants and at least one ...

Details of the company’s participation: Format: Fireside chat and 1x1 investor meetingsDate and • Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 ...

DMT S.A. (BP 270, Savoie-Technolac, F-73375 Le Bourget du Lac), which was only founded in 1990 by its current owners, Darlet and Marchante, has emerged as one of the world's leading suppliers of ...

After hours: February 7 at 7:26:05 PM EST Loading Chart for GHRS ...

Ugo Monye, Chris Jones and Danny Care cover the biggest rugby union stories of the week.

Tony Livesey with late night conversation and in-depth interviews.

After hours: 7:55:49 p.m. EST ...